# Bernard Daugeras

> Bernard Daugeras is a Series A investor at Auriga Partners backing Medical and Nutrition. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Auriga Partners](https://shizune.co/investors/profile/auriga-partners)
- Total investments: 5
- Last investment: Oct 2006
- Lead investor: 0%
- Last updated: Aug 2026

Bernard Daugeras is a Series A investor at Auriga Partners focused on Medical and Nutrition. Co-founder Chairman of the Board of Auriga Partners, Bernard is an expert in Life Sciences and was behind successful investments such as BioAlliance Pharma , NicOx. He is a member of the French Academy of Technologies. Bernard began his career doing research into particle physics at the University of Orsay, the University of California atBerkeley, and CNRS, the French national scientific research center. He subsequently held senior posts at the French Ministry of Industry and Research, where he was in charge of promoting technology transfer from research institutions and of optimizing relations between Research and Industry. After 4 years in the Crédit Lyonnais setting up the bank's Venture Capital arm, he joined Finovelec in 1990. Bernard is a graduate of the Ecole Polytechnique and has a PhD from the University of Orsay.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 20% |
| Nutrition | 1 | 20% |
| Health Care | 1 | 20% |
| Therapeutics | 1 | 20% |
| Biotechnology | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Funding Round | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $9M | Series C | Oct 01, 2006 |  |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $17.6M | Series B | May 01, 2004 |  |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $3.3M | Series A | Feb 01, 2002 |  |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $2.2M |  |  |  |
| Isocell | GliSODin Skin Nutrients is a professional medical line of nutricosmetics focused on optimal internal support. It provides the skin with essential nutrients and functions to protect it from the effects of oxidative stress. GliSODin Skin Nutrients was founded in 2008 and is based in Paris, France. | $3.3M | Series A |  |  |

5 of 5 investments shown.

## Co-investors
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together
- [Siparex Groupe](https://shizune.co/investors/profile/groupe-siparex) — VC Fund, 2 deals together
- [Idinvest Partners](https://shizune.co/investors/profile/idinvest-partners) — VC Fund, 2 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 1 deal together

## About Auriga Partners

VC Fund · Paris, France

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.

5 contacts available at Auriga Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Sébastien Descarpentries | Partner | https://shizune.co/investors/profile/sbastien-descarpentries |
| Anne Sossou Hounto | Legal assistant | https://shizune.co/investors/profile/anne-sossou-hounto |
| Arnaud-Guilhem Le Ribault | Partner | https://shizune.co/investors/profile/arnaud-guilhem-le-ribault |
| Bernard Daugeras | Co-founder | https://shizune.co/investors/profile/bernard-daugeras |
| Françoise Lugand | Office manager | https://shizune.co/investors/profile/franoise-lugand |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bernard Daugeras invest in?

Bernard Daugeras invests primarily in Medical, Nutrition and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bernard Daugeras last invest?

The most recent investment recorded for Bernard Daugeras closed in Oct 2006. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co